Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Notes Payables (2023 - 2025)

Perspective Therapeutics (CATX) has disclosed Notes Payables for 3 consecutive years, with $56000.0 as the latest value for Q4 2025.

  • Quarterly Notes Payables rose 7.69% to $56000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56000.0 through Dec 2025, up 7.69% year-over-year, with the annual reading at $56000.0 for FY2025, 7.69% up from the prior year.
  • Notes Payables hit $56000.0 in Q4 2025 for Perspective Therapeutics, up from $55000.0 in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $1.8 million in Q2 2023 to a low of $48000.0 in Q3 2023.
  • Historically, Notes Payables has averaged $197833.3 across 3 years, with a median of $53500.0 in 2024.
  • Biggest five-year swings in Notes Payables: crashed 96.95% in 2024 and later increased 7.84% in 2025.
  • Year by year, Notes Payables stood at $49000.0 in 2023, then rose by 6.12% to $52000.0 in 2024, then rose by 7.69% to $56000.0 in 2025.
  • Business Quant data shows Notes Payables for CATX at $56000.0 in Q4 2025, $55000.0 in Q3 2025, and $54000.0 in Q2 2025.